Historical Timeline

1985   Frank McCormick, Ph.D., begins cancer research program at Cetus Corporation
1991   Cetus Corporation merges with Chiron Corporation
1992   Onyx Pharmaceuticals is founded by Frank McCormick to discover and develop cancer therapeutics and is spun out of the Cetus and Chiron merger as privately held company
1993   Onyx appoints Hollings Renton as the company's first president & CEO
1994   Onyx and Bayer HealthCare Pharmaceuticals form collaboration
1995   Onyx and Warner Lambert, now Pfizer, form collaboration to develop therapeutics for cell cycle regulation
1996  

Frank McCormick leaves Onyx to become head of the University of California, San Francisco Cancer Research Institute

Onyx completes IPO and is listed on the Nasdaq under stock symbol ONXX

1998   Onyx and Warner Lambert, now Pfizer, extend collaboration in area of cell cycle regulation
2000   BAY 43-9006 (now Nexavar), an oral targeted therapy, enters clinical testing
2003   Onyx focuses its efforts solely on the development of BAY 43-9006 and discontinues therapeutic virus program
2004   PD 332991, an oral, cell cycle inhibitor, enters clinical testing
2005   Nexavar is approved for the treatment of patients with advanced kidney cancer; the first new drug in more than a decade for this disease
2007  

Pivotal kidney cancer study (TARGET) published in The New England Journal of Medicine

Nexavar is approved as the first and only targeted therapy for the treatment of patients with unresectable liver cancer

2008  

Hollings Renton retires as chairman and CEO of Onyx

Tony Coles, M.D., joins Onyx as president and CEO

Pivotal liver cancer study (SHARP) published in The New England Journal of Medicine

Onyx acquires ONX 0801, a novel targeted oncology compound in preclinical development

Onyx acquires options to license rights to two JAK 2 inhibitors, ONX 0803 and ONX 0805, with potential broad utility in multiple diseases

2009  

Onyx and Bayer report positive results from a Phase 2 trial evaluating Nexavar plus chemotherapeutic agent, capecitabine, in patients with advanced breast cancer

Onyx acquires Proteolix Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of patients with cancer and autoimmune diseases